1899 related articles for article (PubMed ID: 28331098)
1. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
[TBL] [Abstract][Full Text] [Related]
2. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
3. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
[TBL] [Abstract][Full Text] [Related]
4. A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge.
Domi A; Feldmann F; Basu R; McCurley N; Shifflett K; Emanuel J; Hellerstein MS; Guirakhoo F; Orlandi C; Flinko R; Lewis GK; Hanley PW; Feldmann H; Robinson HL; Marzi A
Sci Rep; 2018 Jan; 8(1):864. PubMed ID: 29339750
[TBL] [Abstract][Full Text] [Related]
5. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections.
Swenson DL; Warfield KL; Negley DL; Schmaljohn A; Aman MJ; Bavari S
Vaccine; 2005 Apr; 23(23):3033-42. PubMed ID: 15811650
[TBL] [Abstract][Full Text] [Related]
6. A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses.
Wu F; Zhang S; Zhang Y; Mo R; Yan F; Wang H; Wong G; Chi H; Wang T; Feng N; Gao Y; Xia X; Zhao Y; Yang S
Viruses; 2020 Jan; 12(1):. PubMed ID: 31947873
[TBL] [Abstract][Full Text] [Related]
7. Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans.
Vu H; Shulenin S; Grolla A; Audet J; He S; Kobinger G; Unfer RC; Warfield KL; Aman MJ; Holtsberg FW
Antiviral Res; 2016 Feb; 126():55-61. PubMed ID: 26681387
[TBL] [Abstract][Full Text] [Related]
8. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.
Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
J Virol; 2017 May; 91(10):. PubMed ID: 28250127
[TBL] [Abstract][Full Text] [Related]
9. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
[TBL] [Abstract][Full Text] [Related]
10. Enhanced
Chabot S; Gimie Y; Obeid K; Kim J; Meseda CA; Konduru K; Kaplan G; Sheng Fowler L; Weir JP; Peden K; Major ME
J Virol; 2022 Sep; 96(18):e0116621. PubMed ID: 36069549
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
12. First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
Bockstal V; Shukarev G; McLean C; Goldstein N; Bart S; Gaddah A; Anumenden D; Stoop JN; Marit de Groot A; Pau MG; Hendriks J; De Rosa SC; Cohen KW; McElrath MJ; Callendret B; Luhn K; Douoguih M; Robinson C
PLoS One; 2022; 17(10):e0274906. PubMed ID: 36197845
[TBL] [Abstract][Full Text] [Related]
13. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.
Martins K; Carra JH; Cooper CL; Kwilas SA; Robinson CG; Shurtleff AC; Schokman RD; Kuehl KA; Wells JB; Steffens JT; van Tongeren SA; Hooper JW; Bavari S
Viral Immunol; 2015 Feb; 28(1):62-70. PubMed ID: 25514232
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitin Ligase WWP1 Interacts with Ebola Virus VP40 To Regulate Egress.
Han Z; Sagum CA; Takizawa F; Ruthel G; Berry CT; Kong J; Sunyer JO; Freedman BD; Bedford MT; Sidhu SS; Sudol M; Harty RN
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768865
[TBL] [Abstract][Full Text] [Related]
15. Defining the multiplicity and time of infection for the production of Zaire Ebola virus-like particles in the insect cell-baculovirus expression system.
Pastor AR; González-Domínguez G; Díaz-Salinas MA; Ramírez OT; Palomares LA
Vaccine; 2019 Nov; 37(47):6962-6969. PubMed ID: 31262589
[TBL] [Abstract][Full Text] [Related]
16. Intranasal immunization with recombinant Vaccinia virus Tiantan harboring Zaire Ebola virus gp elicited systemic and mucosal neutralizing antibody in mice.
Xie L; Zai J; Yi K; Li Y
Vaccine; 2019 May; 37(25):3335-3342. PubMed ID: 31076161
[TBL] [Abstract][Full Text] [Related]
17. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
[TBL] [Abstract][Full Text] [Related]
18. The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform.
Volkmann A; Williamson AL; Weidenthaler H; Meyer TPH; Robertson JS; Excler JL; Condit RC; Evans E; Smith ER; Kim D; Chen RT;
Vaccine; 2021 May; 39(22):3067-3080. PubMed ID: 33077299
[TBL] [Abstract][Full Text] [Related]
19. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
[TBL] [Abstract][Full Text] [Related]
20. Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein.
Kupke A; Volz A; Dietzel E; Freudenstein A; Schmidt J; Shams-Eldin H; Jany S; Sauerhering L; Krähling V; Gellhorn Serra M; Herden C; Eickmann M; Becker S; Sutter G
Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
